ArticleCureus2024
Safety and Efficacy of Jenacid® Herbal Product Against Indomethacin-Induced Ulcers in Albino Wistar Rats.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundJenacid Herbal Product (JHP) used for treating peptic ulcer disease in Uganda, sold over the counter, is approved by the National Drug Authority as a Traditional Herbal Product number THP 482. There have been no published studies on its safety and efficacy.
objectiveThis study aimed to assess potential acute and subacute toxicity as well as the efficacy of JHP.
methodAn acute toxicity test was performed on Swiss Albino Wistar rats using Lorke's method at single oral doses of 10-5000 mg/kg. General change in behavior, adverse effects, and mortality were determined. In the subacute study, Wistar rats received daily oral doses of 250, 500, and 1000 mg/kg of JHP for 28 days. Body weight and biochemical and hematological parameters were measured at the end of the experiment. For the efficacy study, rats were randomly grouped into six groups (n=5). Gastric ulceration induced with a single oral dose of indomethacin 25 mg/kg. One group was humanely sacrificed under halothane anesthesia to confirm ulceration. Treatments included distilled water (negative control), 20 mg/kg omeprazole (positive control), 250, 500, and 1000 mg/kg of JHP for seven days, after which animals were sacrificed, stomachs excised out, observed for gastric lesions (number and severity), and scored.
resultsThe acute toxicity study showed oral LD50 of JHP was above 5000 mg/kg. A subacute toxicity study of JHP had no observable toxicity symptoms or significant variation in body weight, food and water consumption, hematological parameters, or mortality. Elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were noted at 1000 mg/kg but within normal ranges. A significant decrease in total protein was observed at 500 mg/kg and 1000 mg/kg. JHP demonstrated ulcer-healing properties, with the highest efficacy at 500 mg/kg.
conclusionJHP is effective against ulcers with no significant adverse effects. However, chronic use of very high doses may cause a reduction in total protein levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.